The harm benefit analysis (HBA) is the cornerstone of animal research regulation and is considered to be a key ethical safeguard for animals. The HBA involves weighing the anticipated benefits of animal research against its predicted harms to animals but there are doubts about how objective and accountable this process is.
i. To explore the harms to animals involved in pre-clinical animal studies and to assess these against the benefits for humans accruing from these studies; ii. To test the feasibility of conducting this type of retrospective HBA.
Data on harms were systematically extracted from a sample of pre-clinical animal studies whose clinical relevance had already been investigated by comparing systematic reviews of the animal studies with systematic reviews of human studies for the same interventions (antifibrinolytics for haemorrhage, bisphosphonates for osteoporosis, corticosteroids for brain injury, Tirilazad for stroke, antenatal corticosteroids for neonatal respiratory distress and thrombolytics for stroke). Clinical relevance was also explored in terms of current clinical practice. Harms were categorised for severity using an expert panel. The quality of the research and its impact were considered. Bateson’s Cube was used to conduct the HBA.
The most common assessment of animal harms by the expert panel was ‘severe’. Reported use of analgesia was rare and some animals (including most neonates) endured significant procedures with no, or only light, anaesthesia reported. Some animals suffered iatrogenic harms. Many were kept alive for long periods post-experimentally but only 1% of studies reported post-operative care. A third of studies reported that some animals died prior to endpoints. All the studies were of poor quality. Having weighed the actual harms to animals against the actual clinical benefits accruing from these studies, and taking into account the quality of the research and its impact, less than 7% of the studies were permissible according to Bateson’s Cube: only the moderate bisphosphonate studies appeared to minimise harms to animals whilst being associated with benefit for humans.
This is the first time the accountability of the HBA has been systematically explored across a range of pre-clinical animal studies. The regulatory systems in place when these studies were conducted failed to safeguard animals from severe suffering or to ensure that only beneficial, scientifically rigorous research was conducted. Our findings indicate a pressing need to: i. review regulations, particularly those that permit animals to suffer severe harms; ii. reform the processes of prospectively assessing pre-clinical animal studies to make them fit for purpose; and iii. systematically evaluate the benefits of pre-clinical animal research to permit a more realistic assessment of its likely future benefits.
Citation: Pound P, Nicol CJ (2018) Retrospective harm benefit analysis of pre-clinical animal research for six treatment interventions. PLoS ONE 13(3): e0193758. https://doi.org/10.1371/journal.pone.0193758
Editor: I Anna S. Olsson, Universidade do Porto Instituto de Biologia Molecular e Celular, PORTUGAL
Received: July 4, 2017; Accepted: February 16, 2018; Published: March 28, 2018
Copyright: © 2018 Pound, Nicol. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: Extracted data and summaries of extracted data are available in the Dryad public repository: https://doi.org/10.5061/dryad.k2ff3.
Funding: The study was funded by a donation to the University of Bristol from Lucy and Marius Maxwell. The funders had no role in the choice of question, study design, or in the collection, analysis or interpretation of data, nor in the writing of the report, nor the decision to submit the article for publication. The researcher is completely independent of the funders and the funders have not seen the submitted paper.
Competing interests: Pandora Pound has read the journal’s policy and the authors of this manuscript have the following competing interests: Funding from Lucy and Marius Maxwell as described above. Christine Nicol declares that no competing interests exist. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Many countries require research projects using animals to be independently evaluated by a competent authority as part of the approval or licensing process. This prospective evaluation often involves weighing the anticipated benefits of the research against its predicted harms to animals. In the European Union (EU) a harm benefit analysis (HBA) is conducted to assess ‘whether the harm to the animals in terms of suffering, pain and distress is justified by the expected outcome’ and whether the research ‘may ultimately benefit human beings, animals or the environment.’ (Article 38) The HBA has been a legal requirement in the UK since the Animals (Scientific Procedures) Act 1986. Since then several other countries including Norway, Brazil, Tanzania and Australia have adopted similar provisions. Scientists using animals for research in European Union (EU) member states have been required to conduct a HBA since 2013. Whilst the United States Department of Agriculture Animal Welfare Act does not require a HBA to be performed, the US Institutional Animal Care and use Committee is obliged to weigh the objectives of each study against its potential harms to animals. Elsewhere there appears to be no formal requirement for a HBA, with animal research being conducted according to guiding principles (e.g. Japan), local laws, or subject to approval by ethics committees (e.g. Canada).
There are growing doubts about whether the HBA process is sufficiently consistent and objective, with increasing calls for it to become more transparent, systematic and accountable.[2–11] The UK government’s Animals in Science Committee (ASC), has recently recommended that methods for prospectively assessing harms and benefits should be continually improved and updated and that societal concerns about animal research should be explored and addressed. Public support for animal research is conditional upon the minimisation of harms to animals and upon benefits to humans and other animals; however in the UK at least, only 41% of the public trusts scientists not to cause unnecessary suffering to animals. At present public scrutiny of the HBA process is not possible because although non-technical project summaries of approved license applications are publicly available in the UK and other EU countries, they do not include the severity category of the research and cannot be linked to publications reporting the outcome of that research (due to anonymity). Directive 2010/63/EU (Article 39: 2) requires researchers using non-human primates and /or severe procedures to conduct retrospective assessments of their individual projects but it is unclear whether these will be made publicly available.
Accountability however, can be explored by investigating the outcomes of earlier decisions to approve animal studies, i.e. by finding out what benefits have actually accrued from animal studies that have already been conducted and what these studies actually involved in terms of harms to animals. This type of retrospective HBA might also improve the process of conducting prospective HBAs, by suggesting criteria for assessing benefits or by providing a more realistic view of the likely benefit of animal studies based on past experience. Whilst potential benefits might include increased knowledge or safety, our interest here is in the clinical benefit of animal research for humans. However there are challenges involved in this type of retrospective HBA, particularly with regard to determining clinical benefit. The ideal is to use systematic review data (rather than data from single studies) but while systematic reviews of pre-clinical animal studies investigate treatment effects in animals (and scientific rigour) they do not tend to consider relevance for humans. Thus the immediate obstacle to conducting a retrospective HBA of pre-clinical animal research is the lack of systematic data available on clinical benefit.
There have been various attempts to evaluate the clinical benefits of animal research for humans, including consulting physicians for their views, historical investigation of drug developments,[17, 18] citation analysis to track the flow of knowledge from the laboratory to the clinic, tracking studies that clearly indicate future clinical application, assessing research ‘payback’ and comparing findings from systematic reviews of animal studies with systematic reviews of humans studies for the same interventions.  After considering the available options we decided that the latter study, published in 2007 by Perel et al, provided the most suitable data for a retrospective HBA, not only because the study was rigorous and considered a range of treatment interventions but also because the studies reviewed had been conducted sufficiently long ago for their clinical benefits to be assessed.
Our aims were to reanalyse Perel et al’s data to i. explore the actual harms to animals involved in the studies and to assess these against the actual benefits for humans accruing from these studies; and ii. test the feasibility of the retrospective HBA method. To our knowledge this is the first time this type of systematic retrospective HBA has been attempted.
Perel et al’s sample
Perel et al identified 6 interventions for which there was unambiguous systematic review evidence of a treatment effect for humans: corticosteroids for brain injury, antenatal corticosteroids for neonatal respiratory distress, bisphosphonates for osteoporosis, antifibrinolytics for haemorrhage, thrombolytics for stroke and Tirilazad for stroke. Having identified these interventions, they searched for all published and unpublished controlled animal studies for the same 6 interventions, with no restriction by date of publication. To be eligible for inclusion the studies had to report outcomes corresponding to those for which a treatment effect (either positive or negative) had been shown in clinical trials. The authors identified and systematically reviewed 228 animal studies relating to the 6 interventions. They assessed the methodological quality of the animal studies based on measures taken to prevent bias (allocation concealment, blinded assessment of outcome and random allocation to groups) as ‘poor’ for studies in all 6 interventions. Comparing the results from the systematic reviews of animal studies with the systematic reviews of clinical studies they found that two interventions (bisphosphonates, thrombolytics) were concordant, i.e. the findings from the animal studies agreed with the findings from the human studies, one intervention was partially concordant (antenatal corticosteroids) and three were discordant (corticosteroids, Tirilazad and antifibrinolytics). Concordance between animal and human studies suggests that the animal studies represent or model the human condition adequately. Thus concordance provides an indication of clinical relevance, although it does not necessarily imply that the animal studies led directly to human benefit. A limitation is that Perel et al do not state how they selected the 6 interventions from among other potentially relevant interventions, but as our purpose is to test the feasibility of conducting a retrospective HBA (not to obtain a random sample of animal research), their sample is appropriate, particularly since it contains a range of interventions and spread in terms of concordance/ discordance. We searched for the 228 animal studies and noted their citation scores at the time of retrieval (May—June 2015).
Data extraction on harms
Perel et al did not document animal harms, nor welfare and reported animal numbers only where methodologically relevant. We systematically extracted data on harms, welfare and animal numbers from each of the studies, with a second reviewer conducting independent data extraction on a random sample of 20% of papers (n = 42) to check the accuracy and consistency of the process.
We extracted data on the procedures animals underwent, including use of anaesthesia, paralytic agents or painkillers, post-operative care, how and when animals were killed, any unexpected deaths or events and the species and number of animals used. Every effort was made to correctly document animal numbers (by carefully scrutinising the text and tables) but due to poor reporting estimates occasionally had to be made using all available information. We have indicated where this is the case.
We extracted welfare information where this was available, including any mention of diet, water and housing (i.e. individual / group housing, paddocks, metabolic cages, temperature, lighting). Very rarely information was found on animal stress, purchase, quarantine, transport, handling, breeding, mating and monitoring; this was also extracted. We noted whether studies reported that they had ethical approval or had followed guidelines.
Expert panel to categorise the severity of harms
A panel of experts from the School of Veterinary Sciences (University of Bristol) was convened to categorise the severity of harms. The panel consisted of 2 professors, 3 senior research fellows and 1 senior lecturer in animal welfare. Five of the panel members have PhDs in animal welfare science, 3 are veterinary surgeons (2 holding the RCVS Diploma in Animal Welfare Science, Ethics and Law) and all are actively engaged in animal welfare research (including pain perception in rats and sheep, assessment of central pain processing in dogs, development of automated tests of laboratory animal welfare, and humane slaughter of farm, laboratory and wild animals).
The EU’s severity classification (Annex VIII) was used since it is employed by the EU regulatory bodies when performing HBAs and because it is similar to the American system; both classify pain, suffering and distress into categories of mild, moderate or severe. The first author ran the scoring workshop and the second author observed. Rather than asking the panel to assess all the studies, members were asked to assess typical procedures for each of the 6 interventions (corticosteroids, thrombolytics, etc.), including a range of actual endpoints. The antifibrinolytic studies were too varied to summarise as they employed markedly different methods of inducing bleeding and aimed to treat a range of different conditions (e.g. haemorrhage, haematuria, gastric haemorrhage, microarterial trauma) so all studies were presented in this case. (The other studies used a more homogenous range of methods and models to treat single conditions.) Panel members were asked to independently categorise the overall impact of the procedures employed for each of the 6 interventions as mild, moderate, or severe. Non-recovery procedures were excluded where this was clear (Box 1).
Box 1. Severity categorised according to directive 2010/63/EU
Procedures on animals as a result of which the animals are likely to experience short-term mild pain, suffering or distress, as well as procedures with no significant impairment of the well-being or general condition of the animals.
Procedures on animals as a result of which the animals are likely to experience short-term moderate pain, suffering or distress, or long-lasting mild pain, suffering or distress, as well as procedures that are likely to cause moderate impairment of the well-being or general condition of the animals.
Procedures on animals as a result of which the animals are likely to experience severe pain, suffering or distress, or long-lasting moderate pain, suffering or distress, as well as procedures that are likely to cause severe impairment of the well-being or general condition of the animals.
Benefit was assessed in terms of clinical relevance. Clinical relevance was indicated by: i. concordance / discordance between the findings from systematic reviews of animal and human studies for the same interventions, with concordance suggesting that animal studies model the human condition adequately, and ii. current clinical practice relating to the 6 interventions.
Extracted textual data were content analysed. Quantitative data were aggregated. The analysis of harms and benefits was guided by Bateson’s Cube (Fig 1). Bateson’s Cube was designed to guide decision-making for authorising individual animal studies but in practice it has proved difficult to use prospectively. We tested its use as a guide to conducting a retrospective HBA.
We used the most recent version of Bateson’s Cube which consists of 3 axes assessing animal suffering, the likelihood of benefit and the importance of research. (The axes on the original version of the cube were animal suffering, certainty of medical benefit and quality of research, respectively.) According to Bateson the ‘importance of research’ axis refers to both research quality and conceptual advances unrelated to clinical benefit. For this axis we use Perel et al’s assessments of research quality, but we cannot ascertain whether the studies produced conceptual advances unrelated to clinical benefit. Citation scores, however, are able to indicate the broad (not necessarily clinical) impact of the animal studies and are used as such in this context. Box 2 shows the data used for each of the axes. According to Bateson, if the three assessments fall into the solid part of the cube the project is unacceptable.
Box 2. Data for the 3 axes of Bateson’s cube
Animal suffering axis: extracted data on harms, expert panel severity classifications
Likelihood of benefit axis: concordance between animal and human studies, current clinical practice
Importance of research axis: Perel et al’s assessment of research quality, citation scores for the animal studies
Box 3 outlines the terminology used in this paper.
Box 3. Terminology
Interventions: the 6 different treatments being tested, i.e. antifibrinolytics, thrombolytics etc.
Studies: the 228 studies conducted to test the interventions
Experiments: one or more experiments may be conducted within individual studies
Procedures: the actions performed on animals during experiments, categorised for severity as part of the HBA
Harms: the pain, suffering or distress animals may experience during, and/ or as a result of, procedures
Animal model: where animals are used to ‘model’, or mimic, human conditions
Endpoint: the planned time for completion of the experiment, when animals are killed (NB: these are not predefined humane endpoints)
Two hundred and twelve of the 228 papers reviewed by Perel et al were obtained. Fifteen papers, all on thrombolytic therapy for stroke, could not be traced despite the help of experienced librarians. A further paper was excluded as it was a review. The references and missing papers are listed in S1 File. References to the 228 animal studies.
Agreement between the 2 independent data extractors was very high for most items (average 93% agreement) except for the item on the number of animals used (79% agreement).
The United States was the most common location for the research, followed by Europe and Japan (Table 1). Just over half the studies (52%) were conducted by universities, followed by hospital and university collaborations (17%), pharmaceutical company collaborations (9%), pharmaceutical companies alone (8%) and other institutes and collaborations (13%). They span the years 1967 to 2005, with most studies conducted in the 1990s for all interventions except for the bisphosphonate and thrombolytic studies, of which more were conducted in the 2000s than other decades. The studies involved an estimated 27,149 animals, including rats, mice, guinea pigs, rabbits, pigs, non-human primates (baboons, monkeys, squirrel monkeys), cats, sheep and cows. All studies used animals as models of human conditions, rather than for regulatory purposes.
The animal studies were first published before human studies in the case of antifibrinolytics, bisphosphonates and Tirilazad, at around the same time for antenatal corticosteroids, but after human studies in the case of corticosteroids and thrombolytics (Table 2). In the case of bisphosphonates, Tirilazad and thrombolytics, publication of animal studies continued after the systematic reviews of the clinical trials were published.
Reporting of animal harms and welfare was poor (Table 3) and the information reported was basic. Reporting of animal numbers was poor, particularly for studies of antenatal corticosteroids, where foetuses might be studied in ‘batches’, with their tissues and blood ‘pooled’. Thirty two percent of all studies (n = 69) failed to report how animals were killed and 10% (n = 21) did not report when they were killed. Seventy percent (n = 148) failed to report any welfare information and only 3 studies reported post-operative care (one simply mentioned that animals were given post-operative care, one reported use of analgesia and penicillin, one reported that animals were monitored and released to gang cages). Thirteen percent of studies (n = 27) failed to report use of anaesthesia and 97% (n = 206) did not report analgesia use. Half of all studies made no ethical statement. Thirty nine studies (18%) reported additional procedures involving further animals but gave little information on the animal numbers or procedures involved. See S1 Table. Additional procedures involving further animals.
Much of the data presented below is summarised in Table 3 above and Tables 4, 5 and 6 below. Table 5 summarises the severity assessments. Detailed scoring for each severity assessment is available in S2 Table. Results of expert panel severity classifications.
Antifibrinolytics for haemorrhage.
There were 8 studies of antifibrinolytics (aprotinin, aminocaproic acid and tranexamic acid) using various models of blood loss. Six hundred and sixty eight animals were used (485 rats, 109 rabbits, 74 pigs) with an average 83 animals per study. Anaesthesia was reported in all studies. Four models induced blood loss in rats, rabbits or pigs by cutting the ear or tail, with endpoints ranging from 2 hours to 6 days. Two models induced gastric bleeding in rats, one by pouring hydrochloric acid solution into rats' stomachs and the other by creating mucosal lesions in the stomach. Animals were killed at the end of these experiments or after 6 hours. Two models induced blood loss through surgical injury to the internal organs: the first inflicted renal injuries on rabbits by stabbing, crushing, cutting or punch biopsy, with rabbits followed up for 5–10 days, during which they were housed individually in metabolic cages. The second inflicted liver injuries on pigs by applying a clamp to the lobes of the liver. This study reported the use of restraints and paralytics in addition to painkillers and anaesthesia, with the endpoint either death or four hours. Only one study reported how animals were killed and half (n = 4) reported the experimental endpoint. No deaths before endpoint were reported. It was seldom clear how long anaesthesia was maintained for and consequently it was difficult to determine what animals experienced, or for how long. No unexpected events were reported. Only one study reported using painkillers. Three studies (38%) reported welfare information (access to food and water / metabolic cage use). None gave details of post-operative care. Six (75%) did not make an ethical statement.
These studies were mostly scored as moderate or mild, except for the study that involved renal injuries to rabbits with endpoints of up to 10 days, which was mostly scored as severe. Two studies may have been non-recovery but as this was unclear they were scored, mostly as severe.
Bisphosphonates for osteoporosis.
There were 16 studies of bisphosphonates (mainly alendronate), involving 807 animals (56 baboons, 751 rats) with an average 50 animals per study. The model consisted of ovariectomy followed by drug treatment (usually by oral gavage). Some animals had additional procedures at regular intervals, such as blood and urine tests, bone mineral density measurements, scans and x-rays. Twelve studies (75%) reported using anaesthesia for ovariectomies and/ or additional procedures. Nine studies (56%) reported how animals were killed. All studies reported endpoints, ranging from 4 weeks to 2 years. One study reported deaths prior to endpoint. No unexpected events were reported. No studies reported using paralytic agents. None reported using painkillers. Fourteen studies (88%) reported welfare information (housing/ metabolic cage use/ temperature and lighting /diet and access to water). None gave details of post-operative care. Half made an ethical statement.
This model was mostly scored as moderate, rising to the severe category as the duration of studies increased.
Corticosteroids for brain injury.
There were 17 studies of corticosteroids (mainly methylprednisolone, dexamethasone, betamethasone), involving 2296 animals (1163 mice, 863 rats, 210 guinea pigs, 31 monkeys, 29 cats), with an average 135 animals per study. The model involved inflicting brain injury on animals and testing the effect of corticosteroids on recovery. The most common way of inducing brain injury (14 studies) was to use stunners or devices designed to drop weights or protruding rods onto restrained animals’ heads. Some animals had steel caps fitted to their skulls, or holes drilled in their skulls prior to injury. In two studies injury was inflicted during brain surgery and in another monkeys were attached to a sled that crashed at speed. In 3 studies animals were not anaesthetised and in 2 studies only lightly anaesthetised. No studies reported using painkillers; one reported that analgesics ‘appeared unnecessary’. No studies reported using paralytics. Animals were reported to die upon impact in 8 studies (47%), accounting for an estimated 10–18% of animals in these studies. One study reported post-operative wound infections in 2 animals. Animals were observed for varying lengths of time post injury and some were tested for neurological status and grip using a string test. Fourteen studies (82%) reported endpoints, ranging from 2 hours to 30 days. Nine studies (53%) reported deaths prior to endpoint. Twelve studies (71%) reported how animals were killed; in one study animals were left to die of their injuries. Eight studies (47%) gave welfare information (diet/ access to water). One study mentioned post-operative care. Most studies (76%) made no ethical statement.
This model was mostly scored as severe. All scorers categorised procedures as severe where animals had no or only light anaesthesia. Most endpoints were categorised as severe except for studies of the shortest duration which two scorers categorised as moderate as long as anaesthesia was used. For studies lasting 2–4 weeks all but one scorer categorised harms as severe.
Tirilazad for stroke.
There were 18 studies of Tirilazad, involving an estimated 764 animals (25 cats, 111 rabbits, at least 628 rats), with an average of at least 42 animals per study. The model involved an operation under anaesthesia to occlude the middle cerebral artery (MCA) and subsequent testing of the effect of Tirilazad on recovery. During the operation probes and monitors could be placed on the brain. In some studies hypothermia was also induced. Seven studies (39%) occluded the MCA using monofilament. Animals were usually given Tirilazad intra-peritoneally or intravenously at various time points (up to 24h) post-operatively. Anaesthesia was reported in all 18 studies. Two studies reported using analgesia. One reported using a paralytic agent.
There were 2 broad categories of experiment: i. animals had an operation to occlude the MCA, were given Tirilazad and killed up to 24 hours post-operatively. These experiments tended to involve more surgical procedures; ii. animals had an operation to occlude the MCA, were given Tirilazad and then had daily assessments, with death up to 3 days post-operatively, or at 7 days. Post-operative assessments included MRI scans at 24 hours (under anaesthesia), attempts to arouse animals using tactile and painful stimulation up to 24h post-operatively and daily neurological assessments using methods that included pulling animals’ tails and pushing them to test resistance.
Fifteen studies (83%) reported how animals were killed. Seventeen (94%) reported endpoints, ranging from 4 hours to 7 days. Three (17%) reported deaths before endpoint. In one study involving craniectomy and removal of the eye, 5 animals died up to 2 days post-operatively. Six of the 7 studies that occluded the MCA using a monofilament reported that animals suffered vessel perforation and consequent subarachnoid haemorrhage; 29 animals were ‘excluded’ for this reason. Information relating to welfare was given in 6 studies (33%), mainly relating to pre-operative fasting. One study reported post-operative care, noting that animals were given analgesia and penicillin. Ten studies (56%) made no ethical statement.
All variations of the model were categorised as severe. A variation that reported post-operative analgesia was still categorised as severe, but as potentially ‘less severe’.
Antenatal corticosteroids for neonatal respiratory distress.
There were 56 studies of antenatal corticosteroids (mainly betamethasone, dexamethasone, hydrocortisone) involving an estimated 16,000 animals (2,665 mothers and 13,335 neonates). Of the mothers 1057 were sheep, 727 rats, 699 rabbits, 117 monkeys, 45 cows and 20 baboons. The average number of animals used per study (both mothers and neonates) was estimated at 286. One or more of the following methods were used to administer antenatal corticosteroids: i. administration to pregnant mothers over several weeks before preterm delivery of their neonates. ii. administration to foetuses in utero via injection, laparotomy, intra-amniotic injection or ultrasound-guided foetal injection. iii. administration to foetuses in utero, where mothers were given a hysterotomy and catheters (including tracheal catheters) were placed in foetuses, passing from the uterus through an incision in the mother to her flanks, with drugs delivered for up to 14 days and tracheal fluids withdrawn from some foetuses. iv. administration to neonates after delivery via injection or an endotracheal tube.
Mothers had caesarean section (CS) for preterm delivery of their neonates, after which their neonates were removed. Thirty five studies (62%) reported maternal anaesthesia for CS delivery. Fourteen studies (25%) did not report anaesthesia for CS delivery and 2 studies (4%) reported that no anaesthesia was used (one used sedation only and another reported stretching animals, covering their eyes and removing stitches from a previous operation to deliver neonates). In 5 studies (9%) the mother was killed prior to CS. In addition to CS, further procedures for mothers could include ultrasound scans, amniocentesis, hysterotomy, foetal injections, laparotomy, blood sampling and administration of antibiotics or progesterone. Maternal anaesthesia was reported for additional procedures in 13 studies but not in 11 studies where similar procedures were conducted. In 12 studies (21%) anaesthesia was reported for neither the mother nor the foetus/ neonate. The use of maternal analgesia was reported in only one study. Seventy nine percent of studies (n = 44) did not report the fate of mothers. Twenty percent (n = 11 studies) reported that mothers were killed before or around CS, including 8 that reported manner of death. One study reported that mothers (baboons) were released back to gang cages.
After delivery neonates were either killed or observed for varying lengths of time (up to 6 days). For ventilation studies neonates had endotracheal tubes placed at delivery and were mechanically ventilated for periods ranging from 15 minutes to 24 hours, after which they were killed. Some were given pentobarbital to prevent spontaneous respiration. Some had their tracheas clamped during or after ventilation. Some had catheters inserted, some had agents delivered via intra-tracheal instillations and some had lung fluids aspirated. Foetal / neonatal anaesthesia was reported in 18 studies (32%) but in 25 studies where neonates survived for a period after delivery no anaesthesia was reported, including studies that involved ventilation and placement of catheters and endotracheal tubes. No anaesthesia was reported for foetuses undergoing placement of catheters in utero. Four studies (7%) reported using a paralytic agent in neonates, including 2 for which no anaesthesia was reported. No neonatal analgesia was reported.
Neonates/ foetuses were either killed in utero, at delivery, at various time points post-delivery (5 minutes—6 hours), or after various periods of ventilation (15 minutes—24 hours) or observation (1 to 6 days post-delivery). In 4 studies (7%) neonates were observed to see how long it took them to die post-delivery. Ten studies (18%) did not report how neonates were killed and four (7%) did not report when they were killed. Twenty studies (36%) reported deaths before endpoint, including abortions, dead or macerated foetuses in utero, stillbirths and early postnatal deaths. Fifteen studies (27%) reported at least one unexpected event, including pneumothoraces (involving at least 38 neonates), upper airway leaks during tracheal tube placement (7 neonates), pulmonary interstitial emphysema, oedematous foetuses, premature delivery and mothers not pregnant. No studies provided welfare information about neonates. Fifteen studies (27%) reported information about maternal welfare (animal handling, housing, access to food and water, mating, transportation, stress), including one that gave information on post-delivery care. Thirty eight studies (68%) made no ethical statement.
For both mothers and neonates the models were mostly scored as moderate to severe.
Thrombolytics for stroke.
There were 97 studies of thrombolytics (tissue plasminogen activator, tPA) involving an estimated 6614 animals (3484 rats, 2701 rabbits, 246 mice, 120 guinea pigs, 33 squirrel monkeys, 30 baboons), with an average 68 animals per study. (Two studies did not report numbers so the actual number is higher.) This model involved inducing a stroke and testing the effect of a thrombolytic agent on recovery. On the day before the experiment some animals underwent preparatory surgery under anaesthesia to fabricate a clot, or to place catheters, ligatures or probes. On the day of surgery animals were anaesthetised and a stroke was induced by blocking the carotid and/or cerebral arteries with clots or filaments, or by tying the arteries. During surgery some animals had their skulls opened for the placement of probes and monitors. They were given the thrombolytic agent intravenously. In a variation of the model (11 studies) animals had surgery under anaesthesia to place a catheter, then after recovering from anaesthesia a clot was injected through the catheter to induce a stroke whilst the animals were conscious (and restrained). Anaesthesia was reported in 73 studies (75%). In 13 studies (13%) anaesthesia was reported for some procedures / animal groups but not all and in 11 studies (11%) no anaesthesia was reported. The use of paralytic agents was reported in 6 studies, five in which animals were anaesthetised and one in which baboons had a stroke induced whilst awake. Analgesia was reported in one study.
Post-surgical observation periods could be relatively short (2–24 hours), or could last up to 2 weeks or 2 months. Post-stroke animals frequently had reduced levels of spontaneous activity, rapid involuntary movements of the eye, inability to stand, severely uncoordinated movements and hemiparesis. Some had neurological assessments over 1–4 hours, 1–2 days, or for up to 1 week. Assessments commonly involved being held upside down by the tail or being pushed laterally to test resistance. Others included determining how long rats could remain on a horizontal suspended rotating rod, or how long it took them to remove sticky tape from their paws. Some animals had angiograms, CT or MRI scans post-stroke. For MRI scans animals might be restrained in a head holder with bars in their ears. Anaesthesia appeared to be maintained for scans but this was not always clear. MRI scans could continue for up to 8 hours post stroke, or could be performed at 1, 2 or 7 days.
Sixty two studies (64%) reported how animals were killed and 90% (n = 87) reported when they were killed. Endpoints ranged from up to 6 hours to 2 months, with the most common endpoint being 24 hours post stroke, reported in 35 studies (36%). Nineteen studies (20%) reported endpoints of one week or longer. Thirty seven studies (38%) reported deaths prior to endpoint, mainly in the first 24 hours post-stroke. The causes included haemorrhage, cerebral oedema and ‘technical reasons’. Seventeen studies (18%) reported some type of unexpected event including technical difficulties, failure of procedures, haemorrhage, major bleeding complications, secondary stroke and fatal hypotension. Only 18 studies (19%) reported information on welfare (housing/ temperature and light / access to food and water/ animal purchase / monitoring of experiments / depth of anaesthesia), including one study that noted attempts to attenuate suffering. None gave details of post-operative care. Sixty seven studies (69%) made an ethical statement.
Most scorers categorised the stroke models as severe. Some commented that if the study duration was brief and anaesthesia/ analgesia were used, then studies might score less severely. Scorers categorised models that induced stroke while animals were conscious as severe.
Manner of death (all interventions).
Sixty eight percent of studies (n = 145) reported how animals were killed. The most frequently used method was an overdose of anaesthesia but a wide variety of additional methods were employed. In 7 studies (6 of which were for antenatal corticosteroids) animals were left to die. Methods of death for foetuses included tracheal blockage, strangulation and suffocation.
Summary of harms.
Most of the studies involved severe or mostly severe harms to animals, as indicated both by the data extracted on procedures and the severity classification by the expert panel. As the extracted data support the severity classifications (Table 6) we have used the latter when conducting the HBA.
The only studies that involved mostly moderate harms were those on bisphosphonates. A greater percentage of bisphosphonate studies reported welfare information than other interventions and these studies also reported relatively few deaths before endpoint. Bisphosphonate studies may have involved the least harms for animals.
As noted above, clinical relevance is indicated by concordance between the findings of animal and human studies for the same treatment intervention, and current clinical practice. Antifibrinoloytics reduce surgical bleeding and the need for transfusion in humans and are widely used in current clinical practice; however the animal studies produced inconclusive data. Bisphosphonates increase bone mineral density in animals and in post-menopausal women with osteoporosis. They are recommended as a primary preventative treatment for post-menopausal women with osteoporosis. Corticosteroids benefit animals with head injury but increase the risk of mortality in humans. They are no longer recommended for routine use in people with traumatic head injury. Tirilazad reduces infarct volume and improves neuro-behavioural scores in animals but increases the risk of death and dependency in humans. It is considered to have no role in the current treatment of stroke. Antenatal corticosteroids reduce respiratory distress in both animal and human neonates. They also reduce mortality in humans but the mortality data were inconclusive in animals. The routine clinical use of antenatal corticosteroids for preterm delivery is recommended in hospital settings in high income countries. Thrombolytics reduce infarct volume and improve neuro-behavioural scores in animals but increase haemorrhage risk; in humans they reduce death or dependency despite an increase in haemorrhage. Thrombolytics are used to treat certain categories of ischaemic stroke as long as patients present up to 4.5 hours post-stroke (ideally within 3 hours) and relevant expertise and infrastructure is available,[30, 31] however there has been some controversy over their use.[32–34]
Concordance appears to relate to clinical use, with fully and partially concordant treatment interventions being in clinical use (see Table 7). This suggests that concordance is a good indicator of clinical relevance. Fully concordant interventions (bisphosphonates, thrombolytics) also used relatively low numbers of animals (Table 6) and a greater percentage of studies in fully concordant interventions also made ethical statements (Table 3) and had pharmaceutical company involvement (Table 1) than other interventions. Studies for these interventions were also conducted more recently (Table 1).
As noted above, research importance refers to the quality of the research as well as its broader impact (indicated here by citation scores). Perel et al rated the quality of research as ‘poor’ for studies across all 6 interventions. The average citation scores for the studies ranged from 10 for antifibrinolytics to 76 for bisphosphonates (Table 8), with 50 being the average for all studies.
The citation scores appeared to track clinical relevance, with the two highest scores being for the fully concordant interventions, bisphosphonates and thrombolytics (Table 9).
Retrospective harm-benefit analysis
As noted above, if the three assessments (animal suffering, likelihood of benefit, research importance) fall into the solid part of Bateson’s Cube, the project is deemed unacceptable. We performed the HBA by conducting the three assessments for each of the six treatment interventions (Fig 2).
For the studies of corticosteroids and Tirilazad there was high animal suffering and low (no) clinical benefit. Their research importance is considered to be low since the quality of research was poor and their citation scores were below average. As such these studies fall into the solid part of the cube and should not have been approved. The thrombolytic studies involved high animal suffering. Their research importance is considered to be medium since although the research quality was poor, their citation scores were above average. Due to controversy regarding the use of thrombolytics, as well as the conditions placed upon their use, their clinical benefit is considered to be medium to high. Because of the high animal suffering these studies fall into the solid part of the cube and should not have been approved. The bisphosphonate studies involved mostly moderate, but also some severe, harms. As such they are considered to involve medium and high animal suffering. The research importance for the bisphosphonate studies is considered to be medium because although the citation scores were well above average, the quality of research studies was poor. The clinical benefit of these studies is considered to be high. As such the studies involving moderate suffering fall into the clear part of the cube and were permissible, while those involving severe suffering fall into the solid part and were not permissible.
It was not possible to assess concordance where animal studies had produced inconclusive data, and as concordance was a necessary component of clinical relevance, it made the HBA impossible. Consequently, it was not possible to conduct a HBA for antifibrinolytics, as the data from the animal studies were inconclusive. However the fact that the animal data were inconclusive, combined with the studies’ poor research quality and very low citation scores, suggests that the clinical use of antifibrinolytics may have developed independently of the animal studies. In the case of antenatal corticosteroids, mortality data from the animal studies were inconclusive but there was concordance between the animal and human studies in terms of reducing neonatal respiratory distress. The antenatal corticosteroid studies involved mostly moderate to severe harms for both mothers and neonates. As such they are considered to involve high and medium animal suffering. The research importance for the antenatal corticosteroid studies is considered to be low because their research quality was poor and citation scores are below average. Consequently, despite the clinical benefit of these studies being considered high (not counting the inconclusive mortality data), they fall into the solid parts of the cube and were not permissible.
The moderate bisphosphonate studies then, are the only studies that fall into the clear part of the cube in that they were of medium research importance, appeared to minimise harms to animals and were associated with benefits for humans.
Despite expert help we were unable to find 15 of the original studies, all of which reported research on thrombolytics. However, as the thrombolytic studies were by far the most numerous and because we located the majority of them (n = 97), we are confident that the missing papers did not bias our findings. Furthermore, the thrombolytic studies were homogenous in terms of models used so the missing papers were unlikely to have presented any unusual findings.
This is a re-analysis of an existing study so any limitations in the original study design are reproduced here. Although the sample of interventions was not random it provided a range, both in terms of interventions and in the spread of concordance, discordance and partial concordance. As such it provides a good testing ground for analysing harms and benefits and is appropriate for the purposes of this study. The methodological quality of the animal studies for all 6 interventions was poor; this is not unusual for animal studies[35–39] but it may explain why some of the animal data were inconclusive.
It is possible that the severity classifications could reflect poor reporting of measures taken to alleviate suffering. Members of the scoring panel noted that in the absence of information about analgesia, or duration of anaesthesia, they had to classify some procedures as severe that may potentially have scored less severely. However, it is likely that the classifications reflect actual harms since evidence suggests, for example, that if pain relief is not reported then it was not administered. The classification system itself is not very discriminating and although other systems exist for classifying harms, this one was chosen because it is used by EU regulatory bodies and is similar to the American system.
In terms of exploring concordance between animal and human studies it is important to note that many variables may influence the outcome of both animal and human studies, including research design and reporting and publication bias. Perel et al, for example, found strong evidence of publication bias in their systematic review of animal studies of thrombolytics which may have resulted in the treatment effects of thrombolytics being overestimated. Consequently there is a need for caution when interpreting concordance. Furthermore, concordance does not imply causation, i.e. while it may provide an indication of clinical relevance, it does not necessarily imply that the animal studies led directly to human benefit. Indeed the publication dates of the studies suggest that clinical trials did not follow on directly from animal studies; the animal and human studies often appeared to run concurrently and in some cases human studies preceded animal studies, while in others animal studies continued to be published after the treatment effect was known in humans (see Table 2). This confusing picture suggests a lack of communication between those conducting animal research and those running clinical trials.
We have confirmed the feasibility, both of conducting a retrospective HBA and of collecting data on animal harms from pre-clinical research publications. We found Bateson’s cube to be helpful in guiding the HBA as the principle is clear, namely that research falling into the solid parts of the cube should not be approved. As such it follows a strict principle of disallowing research that is of poor quality or that causes severe suffering.
The studies involved an estimated 27,149 animals, including non-human primates. The most common assessment of animal harms by the expert panel was ‘severe’. Reported use of analgesia was rare and some animals (including most neonates) endured significant procedures with no, or only light, anaesthesia reported. Some animals suffered iatrogenic harms. Many were kept alive for long periods post-experimentally but only 1% of studies reported post-operative care. A third of studies reported that some animals died prior to endpoints. Directive 2010/63/EU (Annex IV) specifies acceptable and unacceptable methods for killing different species of animals, indicating that some of the ways animals in these studies were killed would no longer be considered acceptable. Severe harms however, continue to be permitted within current regulatory frameworks; both Directive 2010/63/EU and current US policy allow severe unalleviated pain, suffering or distress, although it requires strong justification. EU requirements in 2014 to record actual, as well as predicted, harms and to retrospectively assess individual projects categorised as severe may eventually lead to greater adoption of refinement measures, but there is still clearly an urgent need to review regulations that permit animals to suffer severe harms. In the UK the ASC has recently recommended that every establishment and ethical review board develops ways to avoid procedures involving severe suffering, with the ultimate goal of eliminating severe suffering altogether.
Given that many of the studies are now several years old it might be argued that the sort of harms reported in these studies would no longer be inflicted on animals, but critically, we found no indication of a trend towards improvement; thrombolytic studies, of which more were conducted in the 2000s than in other decades (mode year of publication 2002) and corticosteroid studies (mode year of publication 2005), continued to inflict severe harms on animals. All of the studies reviewed here were conducted prior to the publication in 2010 and 2011 of the ARRIVE Guidelines and the Gold Standard Publication Checklist for reporting animal research. As these guidelines are intended to improve not only reporting but also research quality and animal welfare the hope might be that they will ultimately reduce animal suffering. However, neither of these guidelines require reporting on the use of restraints and paralytics, the fate of mothers where foetuses or neonates are used, details of additional related procedures, the severity classification of the research nor humane endpoints (although the ARRIVE guidelines require reporting of welfare-related assessments). Furthermore, the ARRIVE guidelines do not yet appear to have resulted in improved reporting standards. Similarly, while more of the journals that publish animal experiments now require author assurance of adherence to ethical standards, compliance with ethical guidelines does not necessarily lead to actual improvements in animal welfare, nor does nor the fact that experiments have gained ethical approval.[48, 49] Guidelines have the potential to improve reporting standards, provide clear data and ultimately improve animal welfare, but they require enforcement from all concerned, including journals and reviewers.
Our study suggests that bodies involved in funding, reviewing and authorising animal studies need to pay greater attention to possibilities for refinement, particularly the use of predefined humane endpoints and the consistent use of anaesthesia and analgesia, including for neonates and foetuses. Had such refinements been employed in these studies they may well have reduced animal suffering. There is increasing attention to the refinement component of the 3Rs[40, 47, 48, 51] as well as its potential impact on research and this is to be welcomed. However, given the increasing range of non-animal technologies available the potential for replacement should also be robustly addressed at the stage that projects are being considered for approval.
This was not an ‘audit’ of the prospective HBA process; an HBA was not a legal requirement for most of these studies since they were either conducted in countries that do not require a formal HBA, or in Europe prior to 2013. Nevertheless, this is the first time a systematic retrospective HBA of a range of pre-clinical animal studies has been conducted and it is perhaps remarkable that the fitness for purpose and accountability of the prospective HBA has not been previously investigated in this way. As noted above, public support for animal research is conditional upon the minimisation of harms to animals and upon benefits to humans and other animals. This HBA found that that the majority of studies involved severe animal suffering. Many animals suffered severe harms that were not associated with human benefit. Only the moderate bisphosphonate studies, less than 7% of the total, appeared to minimise harms to animals whilst being associated with benefit for humans. Some studies (corticosteroids and Tirilazad) not only inflicted severe suffering on animals but were associated with increased human mortality. The regulatory systems in place when these studies were conducted failed to safeguard animals from severe suffering or to ensure that only beneficial, scientifically rigorous research was conducted.
At present responsibility for the prospective authorisation of animal studies is spread amongst research teams, ethical review boards (Animal Welfare and Ethical Review Boards, or AWERBs in the UK), peer reviewers of funding applications, and licensing bodies (such as the UK’s Home Office). Consequently, crucial checks relating to scientific rigour, likelihood of benefit, the availability of non-animal technologies and the assessment and minimisation of animal harms may be conducted in an inconsistent and disparate manner, with no guarantee that the bodies involved hold the appropriate expertise. Research quality for example, is—in the UK at least–mainly the responsibility of peer reviewers who assess funding applications to determine whether the sample size and experimental design are appropriate. However, the poor quality of the animal studies reviewed here and elsewhere[35, 37, 39, 55, 56] suggests that these aspects are not adequately addressed in the peer review process. To ensure that the HBA is fit for purpose, project applications involving animals need to be rigorously scrutinised to ensure that only scientifically robust studies that minimise animal harms and have a strong likelihood of benefit are authorised. This requires both more accurate prospective assessments and tighter regulatory procedures.
This retrospective HBAs highlights factors that may improve the prospective assessment of animal studies. Whilst research quality and animal harms are already assessed prospectively, it is difficult to predict in advance how important or beneficial a research study will be. Our study found that higher citation scores for animal studies appeared to relate to their clinical relevance. This raises the possibility of using citation scores to investigate a research team’s track record, permitting insight into the likely impact of their future studies. Accurate prediction of a study’s future benefits is more challenging, however, and relatively little effort has gone into improving the accuracy of this aspect of the prospective HBA. The problem is compounded by a tendency among scientists to be over optimistic about the potential benefits of their research, particularly when seeking funding.[57, 58] This optimism, together with an implicit confidence in animal research,[59, 60] is likely to bias assessments towards a prediction of benefit. Yet increasing doubts about the validity of findings derived from animal studies[35–39, 55, 61–65] and their translation to humans[20, 22, 66–70] suggest that such confidence may be unwarranted. So how can the likelihood of only authorising beneficial pre-clinical animal research be increased? First, we found that concordance between animal and human studies appeared to relate to clinical relevance. If animal and human studies within the field of interest are ongoing and are being conducted concurrently (as is often the case), concordance between the animal and human data in that field can be assessed as part of a prospective HBA to investigate the likelihood of the animal studies having clinical relevance. Second, our research found that a greater percentage of studies in concordant interventions had pharmaceutical company involvement; it is possible that pharmaceutical companies influence experimental design for the better, or involve greater communication between pre-clinical and clinical scientists, leading to greater relevance. Further research is needed to explore whether this is the case and what the implications might be.
In terms of regulation, ethical review boards have been described as the lynchpin of the HBA and we suggest that the robustness of the HBA might be enhanced by increasing the level, range and consistency of expertise on such boards so that, in addition to considering animal welfare and refinements, each board includes an expert in statistics and experimental design to guarantee scientific rigour (and ensure that animals’ lives are not ‘wasted’) and an expert in non-animal technologies to guarantee that animal use is absolutely necessary. To enhance the likelihood of only beneficial pre-clinical animal studies being authorised, we recommend that funding and licensing bodies make it a requirement for project applicants, as part of their application, to conduct a systematic review of animal studies in their field[71, 72] and to relate the systematic review findings to the relevant clinical research. This would allow reviewers to assess the status and strength of the evidence in the field, the need for the proposed study (thus avoiding unnecessary replication) and the extent of concordance with any existing clinical data. We also suggest that funding bodies, licensing bodies, peer reviewers and ethical review boards adopt a precautionary approach when assessing animal studies so that instead of automatically making an assumption of benefit, they in fact presume (in line with the evidence noted above) that the research is unlikely to be beneficial. These measures would place the burden of proof on those submitting proposals and encourage them to make a much stronger case for any anticipated benefits. Finally, the involvement of experts from a greater range of disciplines (e.g. epidemiology, public health, clinical research) in the reviewing and authorisation of studies would enable wider questions to be asked, such as ‘Is the aim of this project appropriate?’ and if so, ‘Is animal research the best way to answer it?’
In terms of research, we recommend that the relevance to humans of pre-clinical animal research is systematically evaluated, an undertaking that the UK government’s chief scientific advisor also regards as important. In his 2016 lecture to the animal research community, he asked: ‘To what extent have we as a community, ever subjected our claims about how vital animal research has been to human health to the same level of scrutiny we’d apply to those claiming to have discovered a new cure? And I think if not, we must.’
The HBA is a cornerstone of animal research regulation and is considered to be a key ethical safeguard for animals. This is the first time its accountability has been systematically explored across a range of pre-clinical animal studies. This HBA found that that the majority of studies involved severe animal suffering. Many animals suffered severe harms that were not associated with benefits for humans. Only a small proportion of studies minimised harms to animals whilst being associated with human benefit. The regulatory systems in place when these studies were conducted failed to safeguard animals from severe suffering or to ensure that only beneficial, scientifically rigorous research was conducted. Our findings indicate an urgent need to: i. review regulations, particularly those that permit animals to suffer severe harms; ii. reform the processes of prospectively assessing pre-clinical animal studies to make them fit for purpose; and iii. systematically evaluate the relevance to humans of bodies of pre-clinical animal research that have already been conducted, to provide a more realistic assessment of its likely future benefits and increase the accuracy of prospective HBAs.
S1 File. References to the 228 animal studies.
S1 Table. Additional procedures involving further animals.
We are very grateful to Margaret Maltseva-Williams who conducted independent data extraction on a sample of the studies and to the panel of experts from the School of Veterinary Sciences (University of Bristol) who scored the severity of the interventions. Warm thanks are also due to Gail Davies who made valuable comments on an early draft of this paper.
- 1. European Union. European Union Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. Official Journal of the European Union. 2010;276.
- 2. Brønstad A, Newcomer CE, Decelle T, Everitt JI, Guillen J, Laber K. Current concepts of Harm–Benefit Analysis of Animal Experiments–Report from the AALAS–FELASA Working Group on Harm–Benefit Analysis–Part 1. Laboratory animals. 2016;50(1_suppl):1–20.
- 3. Bateson P. When to experiment on animals. New Scientist. 1986;109(1496):30–2. pmid:11655736
- 4. Porter DG. Ethical scores for animal experiments. Nature. 1992;356(6365):101–2. pmid:1545854
- 5. de Cock Buning T, Theune E. A comparison of three models for ethical evaluation of proposed animal experiments. Animal Welfare. 1994;3(2):107–28. pmid:11660271
- 6. Stafleu F, Tramper R, Vorstenbosch J, Joles J. The ethical acceptability of animal experiments: a proposal for a system to support decision-making. Laboratory Animals. 1999;33(3):295–303. pmid:10780850
- 7. Grimm H. Turning apples into oranges? The harm–benefit analysis and how to take ethical considerations into account. Altern Lab Anim. 2015;43:22–4.
- 8. Griffin G, Clark J, Zurlo J, Ritskes-Hoitinga M. Scientific uses of animals: harm-benefit analysis and complementary approaches to implementing the three Rs. Rev Sci Tech. 2014;33:265–72. pmid:25000799
- 9. Pound P, Blaug R. Transparency and Public Involvement in Animal Research. Alternatives to laboratory animals: ATLA. 2016;44(2):167–73. pmid:27256456
- 10. Laber K, Newcomer CE, Decelle T, Everitt JI, Guillen J, Brønstad A. Recommendations for Addressing Harm–Benefit Analysis and Implementation in Ethical Evaluation–Report from the AALAS–FELASA Working Group on Harm–Benefit Analysis–Part 2. Laboratory animals. 2016;50(1 suppl):21–42.
- 11. Davies GF, Greenhough BJ, Hobson-West P, Kirk RG, Applebee K, Bellingan LC, et al. Developing a collaborative agenda for humanities and social scientific research on laboratory animal science and welfare. PLoS One. 2016;11(7):e0158791. pmid:27428071
- 12. Davies G, Golledge H, Hawkins P, Rowland A, Smith J, Wolfensohn S. Review of harm-benefit analysis in the use of animals in research. London, UK: Animals in Science Committee, 2017 27 November 2017. Report No.
- 13. Mori Ipsos. Public attitudes to animal research in 2016. In: Department for Business EaIS, editor. 2016.
- 14. Home Office. Non-technical summaries granted in 2015 2016.
- 15. European Commission. Caring for animals, aiming for better science. Project evaluation and retropective assessment. Brussels: 2013.
- 16. Comroe JH Jr, Dripps RD. Scientific basis for the support of biomedical science. Biomedical Scientists and Public Policy: Springer; 1978. p. 15–33.
- 17. Greek R, Shanks N, Rice MJ. The history and implications of testing thalidomide on animals. The Journal of Philosophy, Science & Law. 2011;11(3):1–32.
- 18. Reines BP. On the locus of medical discovery. Journal of Medicine and Philosophy. 1991;16(2):183–209. pmid:2061700
- 19. Grant J, Cottrell R, Cluzeau F, Fawcett G. Evaluating “payback” on biomedical research from papers cited in clinical guidelines: applied bibliometric study. Bmj. 2000;320(7242):1107–11. pmid:10775218
- 20. Contopoulos-Ioannidis DG, Ntzani EE, Ioannidis JP. Translation of highly promising basic science research into clinical applications. The American journal of medicine. 2003;114(6):477–84. pmid:12731504
- 21. Wooding S, Hanney SR, Pollitt A, Grant J, Buxton MJ. Understanding factors associated with the translation of cardiovascular research: a multinational case study approach. Implementation Science. 2014;9(1):47. pmid:24755187
- 22. Perel P, Roberts I, Sena E, Wheble P, Briscoe C, Sandercock P, et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. Bmj. 2007;334(7586):197. pmid:17175568
- 23. Guidelines for assigning animals into USDA pain and distress categories, (2009).
- 24. Bateson P. Personal communication. 2017.
- 25. Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. Bmj. 2012;344:e3054. pmid:22611164
- 26. National Institute for Health and Clinical Excellence. Alendronate, Etidronate, Risedronate, Raloxifene and Strontium Ranelate for the Primary Prevention of Osteoporotic Fragility Fractures in Postmenopausal Women: National Institute for Health and Clinical Excellence; 2008.
- 27. Alderson P, Roberts I. Corticosteroids for acute traumatic brain injury. The Cochrane Library. 2005.
- 28. Tirilazad International Steering Committee. Tirilazad for acute ischaemic stroke. Cochrane Database Syst Rev. 2001;4.
- 29. Roberts D BJ, Medley N, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Systematic Review 2017;3.
- 30. National Institute for Health and Clinical Excellence. Alteplase for treating acute ischaemic stroke. Technology appraisal guidance [TA264] National Institute for Health and Clinical Excellence, 26 September 2012.
- 31. RCP. National Clinical Guideline for Stroke. Royal College of Physicians, 2016.
- 32. Lenzer J. Why we can’t trust clinical guidelines. Bmj. 2013;346(58):f3830.
- 33. Brown SG, Macdonald SP, Hankey GJ. Do risks outweigh benefits in thrombolysis for stroke? BMJ. 2013;347:f5215. pmid:23990634
- 34. Sandercock PA, Ricci S. Controversies in Thrombolysis. Current neurology and neuroscience reports. 2017;17(8):60. pmid:28667504
- 35. Kilkenny C, Parsons N, Kadyszewski E, Festing MF, Cuthill IC, Fry D, et al. Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PloS one. 2009;4(11):e7824. pmid:19956596
- 36. Henderson VC, Kimmelman J, Fergusson D, Grimshaw JM, Hackam DG. Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments. PLoS Med. 2013;10(7):e1001489. pmid:23935460
- 37. Henderson VC, Demko N, Hakala A, MacKinnon N, Federico CA, Fergusson D, et al. A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib. Elife. 2015;4:e08351. pmid:26460544
- 38. Tsilidis KK, Panagiotou OA, Sena ES, Aretouli E, Evangelou E, Howells DW, et al. Evaluation of excess significance bias in animal studies of neurological diseases. PLoS Biol. 2013;11(7):e1001609. pmid:23874156
- 39. Hirst JA, Howick J, Aronson JK, Roberts N, Perera R, Koshiaris C, et al. The need for randomization in animal trials: an overview of systematic reviews. PLoS One. 2014;9(6):e98856. pmid:24906117
- 40. Richardson CA, Flecknell PA. Anaesthesia and post-operative analgesia following experimental surgery in laboratory rodents: are we making progress? Anesthesia and Analgesia. 2005;1:3.
- 41. Mellor D, Beausoleil N. Extending the'Five Domains' model for animal welfare assessment to incorporate positive welfare states. Animal Welfare. 2015;24(3):241–53.
- 42. European Commission. Caring for animals, aiming for better science. Severity assessment framework. Brussels: 2012.
- 43. Perel P, Roberts, I, Sena, E, Wheble, P, Sandercock, P, Macleod, et al. Testing treatment on animals: relevance to humans. Final report. 2006.
- 44. Hooijmans CR, Leenaars M, Ritskes-Hoitinga M. A gold standard publication checklist to improve the quality of animal studies, to fully integrate the Three Rs, and to make systematic reviews more feasible. 2010. pmid:20507187
- 45. Baker D, Lidster K, Sottomayor A, Amor S. Two years later: journals are not yet enforcing the ARRIVE guidelines on reporting standards for pre-clinical animal studies. PLoS biology. 2014;12(1):e1001756. pmid:24409096
- 46. Rands SA. Inclusion of policies on ethical standards in animal experiments in biomedical science journals. Journal of the American Association for Laboratory Animal Science. 2011;50(6):901–3. pmid:22330784
- 47. Franco NH, Olsson I. " How sick must your mouse be?"-An analysis of the use of animal models in Huntington's disease research. Alternatives to laboratory animals: ATLA. 2012;40(5):271–83. pmid:23215663
- 48. Franco NH, Correia-Neves M, Olsson IAS. Animal welfare in studies on murine tuberculosis: assessing progress over a 12-year period and the need for further improvement. PloS one. 2012;7(10):e47723. pmid:23110093
- 49. Cressey D. Welfare breach prompts Nature to update policy on publishing animal experiments. Nature. 2015.
- 50. Holman C, Piper SK, Grittner U, Diamantaras AA, Kimmelman J, Siegerink B, et al. Where have all the rodents gone? The effects of attrition in experimental research on cancer and stroke. PLoS Biol. 2016;14(1):e1002331. pmid:26726833
- 51. Percie du Sert N, Alfieri A, Allan SM, Carswell HV, Deuchar GA, Farr TD, et al. The IMPROVE guidelines (ischaemia models: procedural refinements of in vivo experiments). Journal of Cerebral Blood Flow & Metabolism. 2017:0271678X17709185.
- 52. Carbone L, Austin J. Pain and laboratory animals: Publication practices for better data reproducibility and better animal welfare. PloS one. 2016;11(5):e0155001. pmid:27171143
- 53. Gruber FP, Hartung T. Alternatives to animal experimentation in basic research. Altex. 2004;21:3–31.
- 54. NC3Rs. Responsibility in the use of animals in bioscience research: expectations of the major research council and charitable funding bodies. National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), 2017 April 2017. Report No.
- 55. Macleod MR, McLean AL, Kyriakopoulou A, Serghiou S, de Wilde A, Sherratt N, et al. Risk of bias in reports of in vivo research: a focus for improvement. PLoS biology. 2015;13(10):e1002273. pmid:26460723
- 56. Macleod M. Learning lessons from MVA85A, a failed booster vaccine for BCG. BMJ. 2018;360. pmid:29321154
- 57. Pollock N, Williams R. The business of expectations: How promissory organizations shape technology and innovation. Social Studies of Science. 2010;40(4):525–48.
- 58. Brown N. Hope against hype-accountability in biopasts, presents and futures. Science & Technology Studies. 2003.
- 59. Vogt L, Reichlin TS, Nathues C, Würbel H. Authorization of Animal Experiments Is Based on Confidence Rather than Evidence of Scientific Rigor. PLoS Biology. 2016;14(12):e2000598. pmid:27911892
- 60. Reichlin TS, Vogt L, Würbel H. The Researchers’ View of Scientific Rigor—Survey on the Conduct and Reporting of In Vivo Research. PloS one. 2016;11(12):e0165999. pmid:27911901
- 61. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8(6):e1000412. pmid:20613859
- 62. Sena ES, Van Der Worp HB, Bath PM, Howells DW, Macleod MR. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol. 2010;8(3):e1000344. pmid:20361022
- 63. Martić-Kehl MI, Wernery J, Folkers G, Schubiger PA. Quality of Animal Experiments in Anti-Angiogenic Cancer Drug Development–A Systematic Review. PloS one. 2015;10(9):e0137235. pmid:26421849
- 64. McGrath J, Curtis M. BJP is changing its requirements for scientific papers to increase transparency. British journal of pharmacology. 2015;172(11):2671–4.
- 65. Andrews NA, Latrémolière A, Basbaum AI, Mogil JS, Porreca F, Rice AS, et al. Ensuring transparency and minimization of methodologic bias in preclinical pain research: PPRECISE considerations. Pain. 2016;157(4):901–9. pmid:26683237
- 66. Hackam DG, Redelmeier DA. Translation of research evidence from animals to humans. Jama. 2006;296(14):1727–32.
- 67. Ioannidis JP. Extrapolating from animals to humans. Science Translational Medicine. 2012;4(151):151ps15–ps15. pmid:22972841
- 68. Pound P, Bracken MB. Is animal research sufficiently evidence based to be a cornerstone of biomedical research? BMJ. 2014;348.
- 69. Hawkes N. Poor quality animal studies cause clinical trials to follow false leads. BMJ. 2015;351:h5453. pmid:26468237
- 70. Cohen D. Oxford TB vaccine study calls into question selective use of animal data. BMJ. 2018;360. pmid:29321165
- 71. Hooijmans C, Ritskes-Hoitinga M. Progress in using systematic reviews of animal studies to improve translational research. PLoS medicine. 2013;10(7):e1001482. pmid:23874162
- 72. Ritskes-Hoitinga M, Wever K. Improving the conduct, reporting, and appraisal of animal research. British Medical Journal Publishing Group; 2018.
- 73. DeGrazia D, Sebo J. Necessary Conditions for Morally Responsible Animal Research. Cambridge Quarterly of Healthcare Ethics. 2015;24(04):420–30.
- 74. Walport M. Animal Research: Then and Now—Paget Lecture 2016 (Transcript of speech). 80th Stephen Paget Memorial Lecture; Understanding Animal Research2016.